

## Reference Data

#### Business segments and major products



Segments	Description	Major products	
Imaging Products Business	Digital camera-interchangeable lens type Interchangeable lens Compact DSC	Mirrorless Camera [Z 8] Mirrorless Camera [Z f] Image: Camera [Z f]	KOR] Lens [NIKKOR Z 135mm f/1.8 S Plena]
Precision Equipment Business	FPD lithography system Semiconductor lithography system Alignment station Measuring & inspection system	FPD Lithography System [FX-885]	
Healthcare Business	Biological microscope Retinal diagnostic imaging system Contract Cell Manufacturing business	Confocal Microscope System [AX/AX R]	tic Imaging with Guided Swept OCT
Components Business	EUV related component Optical parts, Optical components Encoders and Actuators Photomask substrate for FPD	Optical Parts Optical Components Optical Components	pent actuator units <b>C3 eMotion</b> ]
Digital Manufactur- ing Business	Metal 3D printer Optical processing machine Contract material processing Measuring instrument X-ray system Industrial microscopy	Metal 3D Printer [NXG XII 600]	asuring System VMZ-S Series]

## 3rd quarter of the year ending March 31, 2024: Financial Highlights



Billions of Yen	FY2023/3 Q3 Actual (A)	FY2024/3 Q3 Actual (B)	Cha Amount (B)-(A)	nge % (B)/(A)	
Revenue	167.7	197.7	+30.0	+17.8%	
<b>Operating profit</b> % vs Revenue	26.2 15.6%	<b>20.8</b> 10.5%	-5.4 -5.1P	-20.6%	
Profit before tax % vs Revenue	26.3 15.7%	21.0 10.6%	-5.3 -5.1P	-20.3%	
Profit attributable to owners of parent	20.6	15.1	-5.5	-26.3%	
% vs Revenue	12.3%	7.7%	-4.6P		
FCF	-3.4	23.7	+27.1	-	
Exchange Rate: US\$	¥141	¥148	Impact on Revenue +7.1		
EURO	¥144	¥159	Impact on Op	erating profit	
ECRO	1111	1205	+1.4		

FCF turned positive on improved working capital, the sale of investment securities, and the like.

## 3rd quarter of the year ending March 31, 2024: Performance by Segment



		FY2023/3 Q3	FY2024/3 Q3	Char	
Billions of Yen Imaging Products Business	Revenue Operating profit	Actual (A) 69.9 19.0	Actual (B) 84.3 17.7	Amount (B)-(A) +14.4 -1.3	% (B)/(A) +20.7% -6.5%
Precision Equipment Business	% vs Revenue Revenue Operating profit % vs Revenue	27.2% 50.2 8.1 16.2%	21.1% 58.5 7.9 13.5%	-6.1P +8.3 -0.2 -2.7P	+16.6% -3.1%
Healthcare Business	Revenue Operating profit % vs Revenue	25.5 3.6 14.1%	25.6 0.2 <sub>0.6%</sub>	+0.1 -3.4 -13.5P	+0.3% -95.4%
Components Business	Revenue Operating profit % vs Revenue	11.8 4.4 37.7%	13.6 5.7 42.4%	+1.8 +1.3 +4.7P	+15.3% +29.6%
Digital Manufacturing Business	Revenue Operating profit % vs Revenue	9.8 -1.0 -9.5%	14.8 -3.3 -22.0%	+5.0 -2.3 -12.5P	+51.6% -
Others (incl. Corporate expenses, etc.)	Revenue Operating profit	0.8 -8.0	0.9 -7.5	+0.1 +0.5	+21.2%
Consolidated	Revenue Operating profit % vs Revenue	167.7 26.2 <sup>15.6%</sup>	197.7 20.8 10.5%	+30.0 -5.4 -5.1P	+17.8% -20.6%

Note: FY2023/3 results have been re-stated to reflect segmentation changes.

## Forecast for the year ending March 31, 2024: Financial Highlights



	FY2021/3	FY2022/3		FY2023/	3	FY2	2024/3 For	ecast
Billions of Yen	Full Year	Full Year	1H	2H	Full Year	1H	2H	Full Year
Revenue	451.2	539.6	288.3	339.8	628.1	331.2	373.8	705.0
Operating profit	-56.2	49.9	24.4	30.5	54.9	13.6	22.4	36.0
% vs Revenue	-12.5%	9.3%	8.5%	9.0%	8.7%	4.1%	6.0%	5.1%
Profit before tax	-45.3	57.0	26.0	31.0	57.0	15.2	21.8	37.0
% vs Revenue	-10.0%	10.6%	9.0%	9.1%	9.1%	4.6%	5.8%	5.2%
Profit attributable to owners of parent	-34.4	42.6	18.8	26.1	44.9	9.8	17.2	27.0
% vs Revenue	-7.6%	7.9%	6.5%	7.7%	7.2%	3.0%	4.6%	3.8%
ROE	-6.4%	7.5%		7.4%			4.2%	
EPS	-¥93.96	¥116.23		¥125.46			¥77.96	
Annual Dividends	¥20	¥40	¥45				¥50	
FCF	22.9	30.9		-112.1			-	
Exchange Rate: US\$	¥106	¥112	¥134	¥137	¥135	¥141	¥144	¥143
EURO	¥124	¥131	¥139	¥143	¥141	¥153	¥155	¥154

Note: The number of issued shares assumed for EPS forecast calculation: approx. 346.3M shares

## Forecast for the year ending March 31, 2024: Financial Highlights (Changes from Previous Forecast)



	Previous Forecast (Nov. 9) (A)			New Forecast (Feb. 8) (B)			Change (B)-(A)		
Billions of Yen	1H	2H	Full Year	1H	2H	Full Year	1H	2H	Full Year
Revenue	331.2	358.8	690.0	331.2	373.8	705.0	±0.0	+15.0	+15.0
Operating profit	13.6	20.4	34.0	13.6	22.4	36.0	±0.0	+2.0	+2.0
% vs Revenue	4.1%	5.7%	4.9%	4.1%	6.0%	5.1%	±0.0P	+0.3P	+0.2P
Profit before tax	15.2	21.8	37.0	15.2	21.8	37.0	±0.0	±0.0	±0.0
% vs Revenue	4.6%	6.1%	5.4%	4.6%	5.8%	5.2%	±0.0P	-0.3P	-0.2P
Profit attributable to owners of parent	9.8	17.2	27.0	9.8	17.2	27.0	±0.0	±0.0	±0.0
% vs Revenue	3.0%	4.8%	3.9%	3.0%	4.6%	3.8%	±0.0P	-0.2P	-0.1P
ROE		4.2%	)	4.2%			±0.0P		
EPS		¥77.96	5		¥77.96			±¥0.00	)
Annual Dividends		¥50	)	¥50				±¥C	)
Exchange Rate: US\$	¥141	¥140	¥141	¥141	¥144	¥143	±¥0	+¥4	+¥2
EURO	¥153	¥150	¥152	¥153	¥155	¥154	±¥0	+¥5	+¥2

Note: The numbers of issued shares assumed for EPS forecast calculation: approx. 346.3M shares for both previous forecast (Nov. 9) and new forecast (Feb. 8).

#### Forecast for the year ending March 31, 2024: Forecast by Segment



					FY20	024/3 Fore	ecast
Billions of Yen		1H	2H	Full Year	1H	2H	Full Year
Imaging Products	Revenue	114.5	112.6	227.1	137.6	137.4	275.0
Business	Operating profit	22.2	20.0	42.2	25.2	18.8	44.0
Precision Equipment	Revenue	83.3	119.9	203.2	96.0	117.0	213.0
Business	Operating profit	6.2	18.3	24.5	3.2	8.8	12.0
Healthcare Business	Revenue	46.6	52.7	99.3	51.2	53.8	105.0
	Operating profit	3.6	7.9	11.5	2.7	3.8	6.5
Components Business	Revenue	25.6	27.4	53.0	18.7	28.3	47.0
	Operating profit	11.3	10.7	22.0	5.9	9.1	15.0
Digital Manufacturing	Revenue	16.2	25.8	42.0	26.1	35.9	62.0
Business	Operating profit	-2.8	-7.3	-10.1	-9.5	-3.5	-13.0
Others	Revenue	1.7	1.5	3.2	1.4	1.6	3.0
Others	Operating profit	1.0	1.6	2.6	0.1	3.9	4.0
	Operating profit	-17.2	-20.8	-38.0	-14.1	-18.4	-32.5
Corporate expenses,	Broken out: Expense related to investment in growth	-10.1	-11.6	-21.7	-10.2	-9.8	-20.0
etc.	Broken out: Expense for administration department	-5.8	-7.7	-13.5	-6.8	-9.2	-16.0
	Broken out: Elimination of intersegment transactions	-1.2	-1.5	-2.7	2.9	0.6	3.5
Consolidated	Revenue	288.3	339.8	628.1	331.2	373.8	705.0
Consolidated	Operating profit	24.4	30.5	54.9	13.6	22.4	36.0

Note: FY2023/3 results have been re-stated to reflect segmentation changes.

"Expense related to investment in growth" is expenses mainly related to basic research, expense related to the creation of new businesses, and expense related to manufacturing innovation.

"Expense for administration department" is the general administrative expenses for head office functions, and corporate P/L non-attributable to any reportable segments.

## Forecast for the year ending March 31, 2024: Forecast by Segment (Changes from Previous Forecast)



		Previous Forecast (Nov. 9) (A)			New Forecast (Feb. 8) (B)			Change (B)-(A)		
Billions of Yen		1H	2H	Full Year	1H	2H	Full Year	1H	2H	Full Year
Imaging Products	Revenue	137.6	137.4	275.0	137.6	137.4	275.0	±0.0	±0.0	±0.0
Business	Operating profit	25.2	17.8	43.0	25.2	18.8	44.0	±0.0	+1.0	+1.0
Precision Equipment	Revenue	96.0	104.0	200.0	96.0	117.0	213.0	±0.0	+13.0	+13.0
Business	Operating profit	3.2	4.8	8.0	3.2	8.8	12.0	±0.0	+4.0	+4.0
Healthcare	Revenue	51.2	51.8	103.0	51.2	53.8	105.0	±0.0	+2.0	+2.0
Business	Operating profit	2.7	6.8	9.5	2.7	3.8	6.5	±0.0	-3.0	-3.0
Components	Revenue	18.7	28.3	47.0	18.7	28.3	47.0	±0.0	±0.0	±0.0
Business	Operating profit	5.9	9.1	15.0	5.9	9.1	15.0	±0.0	±0.0	±0.0
Digital Manufacturing	Revenue	26.1	35.9	62.0	26.1	35.9	62.0	±0.0	±0.0	±0.0
Business	Operating profit	-9.5	-3.5	-13.0	-9.5	-3.5	-13.0	±0.0	±0.0	±0.0
Others	Revenue	1.4	1.6	3.0	1.4	1.6	3.0	±0.0	±0.0	±0.0
Others	Operating profit	0.1	3.9	4.0	0.1	3.9	4.0	±0.0	±0.0	±0.0
	Operating profit	-14.1	-18.4	-32.5	-14.1	-18.4	-32.5	±0.0	±0.0	±0.0
Corporate	Broken out: Expense related to investment in growth	-10.2	-9.8	-20.0	-10.2	-9.8	-20.0	±0.0	±0.0	±0.0
expenses, etc.	Broken out: Expense for administration department	-6.8	-9.2	-16.0	-6.8	-9.2	-16.0	±0.0	±0.0	±0.0
	Broken out: Elimination of intersegment transactions	2.9	0.6	3.5	2.9	0.6	3.5	±0.0	±0.0	±0.0
Consolidated	Revenue	331.2	358.8	690.0	331.2	373.8	705.0	±0.0	+15.0	+15.0
Consolidated	Operating profit	13.6	20.4	34.0	13.6	22.4	36.0	±0.0	+2.0	+2.0

Note: "Expense related to investment in growth" is expenses mainly related to basic research, expense related to the creation of new businesses, and expense related to manufacturing innovation.

"Expense for administration department" is the general administrative expenses for head office functions, and corporate P/L non-attributable to any reportable segments.

## 3rd quarter of the year ending March 31, 2024: Quarterly Performance by Segment




		FY2023/3				FY2024/3			
Billions of Yen		Q1	Q2	Q3	Q4	Q1	Q2	Q3	
Imaging Products	Revenue	61.2	53.3	69.9	42.7	74.4	63.2	84.3	
Business	Operating profit	13.6	8.6	19.0	1.0	15.3	9.9	17.7	
Precision Equipment	Revenue	41.4	41.9	50.2	69.7	37.3	58.7	58.5	
Business	Operating profit	3.9	2.3	8.1	10.2	-3.6	6.8	7.9	
Healthcare Business	Revenue	21.7	24.9	25.5	27.2	25.2	26.0	25.6	
Healthcare Business	Operating profit	0.8	2.8	3.6	4.3	1.8	0.9	0.2	
Componente Rusiness	Revenue	12.8	12.8	11.8	15.6	8.4	10.3	13.6	
Components Business	Operating profit	5.9	5.4	4.4	6.3	2.4	3.5	5.7	
Digital Manufacturing	Revenue	7.4	8.8	9.8	16.0	11.9	14.2	14.8	
Business	Operating profit	-0.9	-1.9	-1.0	-6.3	-4.7	-4.8	-3.3	
Others	Revenue	0.9	0.8	0.8	0.7	0.6	0.8	0.9	
others	Operating profit	0.7	0.3	0.0	1.6	-0.0	0.1	1.7	
	Operating profit	-8.7	-8.5	-8.1	-12.7	-7.8	-6.3	-9.2	
	Broken out: Expense related to investment in growth	-5.0	-5.1	-5.6	-6.0	-5.1	-5.1	-5.1	
Corporate expenses, etc.	Broken out: Expense for administration department	-2.7	-3.1	-3.3	-4.4	-3.4	-3.4	-3.5	
	Broken out: Elimination of intersegment transactions	-0.9	-0.3	0.8	-2.3	0.7	2.2	-0.6	
Consolidated	Revenue	145.6	142.7	167.7	172.1	158.1	173.1	197.7	
Consondated	Operating profit	15.3	9.1	26.2	4.3	3.2	10.4	20.8	

Note: FY2023/3 results have been re-stated to reflect segmentation changes.

"Expense related to investment in growth" is expenses mainly related to basic research, expense related to the creation of new businesses, and expense related to manufacturing innovation.

"Expense for administration department" is the general administrative expenses for head office functions, and corporate P/L non-attributable to any reportable segments.






Note: Equity ratio is the ratio of equity attributable to owners of parent to total assets. Cash and cash equivalents excludes time deposits with maturities of three months or more.

# Capital Expenditures, Depreciation & Amortization, and Inventories






Capital expenditures Depreciation & amotization

Note: Capital expenditures include right-of-use assets.

Depreciation & amortization includes right-of-use assets, depreciation of property, plant and equipment and amortization of intangible assets obtained by business combination. Inventories of FY2023/3 results have been re-stated to reflect segmentation changes.


#### 1st to 3rd quarters of the year ending March 31, 2024: Revenue Breakdown





Note: The outside and inside circles show the breakdown of FY2024/3 Q1-Q3 revenue of ¥528.9B and FY2023/3 Q1-Q3 revenue of ¥456.0B, respectively. FY2023/3 results have been re-stated to reflect segmentation changes.






Note: R&D expenditures includes capitalization of some development expenditures. Due to segment revision from FY2024/3, the financial figures for FY2023/3 are displayed according to the reorganized display.


#### Cash Flow History






Note: FCF + CF from financial activities + Effect of exchange rate changes on cash and cash equivalents = net increase (decrease) in cash and cash equivalents






#### Forecast for the year ending March 31, 2024: Precision Equipment Business Sales Units






Note: "i-line, etc." part in numbers of semiconductor lithography systems sales include sales numbers of the "Mini Step & Repeat Exposure System". The unit sales of new semiconductor lithography systems are 38 units in FY2020/3, 23 units in FY2021/3, 17 units in FY2022/3, 27 units in FY2023/3, and 30 units (forecast) in FY2024/3.





36





Note: "i-line, etc." part in numbers of semiconductor lithography systems sales include sales numbers of the "Mini Step & Repeat Exposure System".



	Exchange Rate	Financial Impact from Fluctuation by 1 yen				
	FY2024/3 Forecast for Q4	Revenue Q4	Operating Profit Q4			
US \$	¥140	Approx. ¥0.4billion	Approx.			
EURO	¥150	Approx. ¥0.2billion	¥0.1billion			

Note: The foreign exchange impact above is made on the assumption that emerging-market currencies move according to the influence of US\$ and Euro.

#### Revision of reporting business segments (From FY2024/3)



Old Segment	Business Unit (BU)			Busir	ness Unit (BU)	New Segment
Imaging Products	Imaging BU		]	Imaging BU		Imaging Products
Precision	FPD Lithograp	hy BU		Precision	FPD Lithography BU	Duosisian
Equipment	Semiconducto	r Lithography BU		Equipment Group	Semiconductor	Precision Equipment
Healthcare	Healthcare BU			Group	Lithography BU	_quipment
	Customized Pr	oducts BU	-	Healthcare BL	J	Healthcare
	Glass BU		-	<b>Customized P</b>	roducts BU	
Components	Optical components, etc.		-	Glass BU		Components
	Digital Solutions BU	tions BU Material processing		Digital Solution	ons BU	
		(incl. Morf3D)		→ Industrial Metrology BU		Digital
Industrial	Industrial Metrology BU			Advanced Manufacturing BU		Manufacturing
Metrology and	Others					
Others		SLM		Others*		Others
Corporate expenses, etc.	Headquarters division of the parent company			Headquarters company	division of the parent	Corporate
		Next Generation Project Division	(partly)		Next Generation Project Division	expenses, etc.

Departments and subsidiaries in the Material Processing Business have been consolidated under the Advanced Manufacturing BU and combined with the Industrial Metrology BU to make up the Digital Manufacturing Business segment (aligns with Medium-Term Management Plan business domain).

\* From FY2024/3, domestic production subsidiaries under the Precision Equipment Business have been transferred to the Production Division included under the Others segment



Forward-looking statements for earnings and other performance data contained herein are based on information currently available to the Company, and all potential risks and uncertainties are taken into account. The Company asks that investors understand that changes in conditions may cause actual performance to significantly differ from these projections.

